Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma (12-107)

Clinical Trial ID NCT01943422

Rank	Title	Journal	Year	PubWeight™‹?›
1	Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.	J Clin Oncol	2014	1.47
2	Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.	J Natl Cancer Inst	2016	1.40
3	Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.	Oncotarget	2014	1.33
4	BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.	Onco Targets Ther	2015	0.99
5	Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.	Cancer Biol Med	2014	0.95
6	Understanding the biology of melanoma and therapeutic implications.	Hematol Oncol Clin North Am	2014	0.85
7	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.	Semin Oncol	2015	0.82
8	The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.	Oncotarget	2016	0.79
9	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.	Trends Immunol	2016	0.75